Department of Inorganic Materials, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, 2-3-10 Kanda-Surugadai, Chiyoda, Tokyo 101-0062, Japan.
Biomed Mater. 2010 Dec;5(6):065009. doi: 10.1088/1748-6041/5/6/065009. Epub 2010 Nov 9.
A chitosan/marine-originated collagen composite has been developed. This composite gel was characterized and its biocompatibility, as well as an inflammatory reaction, was observed. The chitosan gel including N-3-carboxypropanoil-6-O-(carboxymethyl) chitosan of 3 mol%, 6-O-(carboxymethyl) chitosan of 62 mol% and 6-O-(carboxymethyl) chitin of 35 mol% was prepared and compounded with the salmon atelocollagen (SA) gel at different mixture ratios. The composite gels were injected subcutaneously in to the back of rats. The specimens were harvested for a histological survey as well as a tumor necrosis factor-alpha (TNF-α) assay by ELISA. The inflammatory cell infiltration and release of TNF-α were successively controlled low with the ratio of SA to chitosan at 10:90 or 20:80. The SA gel first, within 2 weeks, and then chitosan in the composite gel were slowly absorbed after implantation, followed by soft tissue formation. It is expected that this composite gel will be available as a carrier for tissue filler and drug delivery systems.
已经开发出一种壳聚糖/海洋来源胶原蛋白复合材料。对这种复合凝胶进行了表征，并观察了其生物相容性和炎症反应。壳聚糖凝胶由 3 mol%的 N-3-羧丙基-6-O-（羧甲基）壳聚糖、62 mol%的 6-O-（羧甲基）壳聚糖和 35 mol%的 6-O-（羧甲基）壳聚糖组成，并与鲑鱼原胶原蛋白（SA）凝胶以不同的混合比例复合。将复合凝胶注射到大鼠背部的皮下。采集标本进行组织学调查以及通过 ELISA 检测肿瘤坏死因子-α（TNF-α）。随着 SA 与壳聚糖的比例为 10:90 或 20:80，炎症细胞浸润和 TNF-α 的释放被成功地依次控制在较低水平。SA 凝胶首先在 2 周内，然后是复合凝胶中的壳聚糖在植入后被缓慢吸收，随后形成软组织。预计这种复合凝胶将可用作组织填充剂和药物输送系统的载体。
Zotero 插件